metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology The Stroop test validation in the detection of minimal hepatic encephalopathy in...
Información de la revista
Vol. 27. Núm. S3.
Abstracts from XVII Mexican Congress of Hepatology
(diciembre 2022)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 27. Núm. S3.
Abstracts from XVII Mexican Congress of Hepatology
(diciembre 2022)
Open Access
The Stroop test validation in the detection of minimal hepatic encephalopathy in Mexican patients with cirrhosis, preliminary results
Visitas
807
PF Domínguez Cardoso, JL Pérez Hernández, F Higuera de la Tijera, AD Santana Vargas, D Montemira Orozco, CI Hinojosa Segura
Gastroenterology Service. General Hospital of Mexico "Dr. Eduardo Liceaga.” Mexico City, Mexico
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Resumen
Texto completo
Descargar PDF
Estadísticas
Figuras (1)
Suplemento especial
Este artículo forma parte de:
Vol. 27. Núm S3

Abstracts from XVII Mexican Congress of Hepatology

Más datos
Introduction and Objectives

Minimal hepatic encephalopathy (MHE) is an important cause of morbi-mortality in patients with cirrhosis; its timely identification has an impact on prognosis; the Stroop Test is a diagnostic tool that can be useful and practical in these patients. Validating this test and calculating the cut-off point for the diagnosis of MHE in our population is important. This study aimed to validate the Stroop Test application and estimate the cut-off point for the diagnosis of MHE in our population.

Materials and Methods

Observational, cross-sectional and prolective study to validate and calculate the cut-off point of the Stroop Test; patients with cirrhosis with and without manifest hepatic encephalopathy will be included, who will undergo the Stroop Test, psychometric score of hepatic encephalopathy (PHES) and the critical flicker frequency test (CFF): ROC curves will be calculated to measure sensitivity, specificity and its cut-off point, healthy subjects will also be included for comparison. The trial was approved by the research ethics committee, and informed consent was obtained.

Results

One hundred subjects participated: 50 controls, 33 females (66%) age =43.2±12.1 years; and 50 patients with hepatic cirrhosis: 27 females (54%) age 53.2±8.2 years, of which 54%, 42% and 2% were in Child-Pugh A, B and C, respectively. AUROC was calculated for patients with cirrhosis with and without MHE, AUROC= 0.751 (CI=0.656-.846); cut-off point=183.5 sensitivity (SE)=60% specificity (SP)=74% (Figure 1).

Conclusions

For our study sample, we found that the Stroop Test is a good diagnostic tool, taking into account a cut-off point of 183.5 sec. as opposed to 274.9 sec. that the apple application gives us, which is validated in a different population (grade and quality of education).

Funding

Donation by the volunteer ladies of the Hospital General de México “Dr. Eduardo Liceaga.”

Declaration of interest

The authors declare no potential conflicts of interest.

El Texto completo está disponible en PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.aohep.2022.100787
No mostrar más